阿法替尼联合放疗,联合或不联合替莫唑胺,治疗新诊断胶质母细胞瘤患者的I期试验结果
这项I期开放标签3+3剂量递增试验纳入新诊断、组织学证实为4级恶性胶质瘤且O6-甲基鸟嘌呤-DNA甲基转移酶基因启动子甲基化状态明确的患者,评估连续每日阿法替尼联合放疗(联合或不联合替莫唑胺)的最大耐受剂量。55例入组,36例接受至少1剂试验药物(方案M 20例,方案U 16例)。联合每日替莫唑胺和放疗时阿法替尼最大耐受剂量为30 mg,仅联合放疗时为40 mg。
要点
- 联合每日替莫唑胺和放疗时,阿法替尼最大耐受剂量为30 mg。
- 仅联合放疗时,阿法替尼最大耐受剂量为40 mg。
- 最常见不良事件为腹泻和皮疹,未发现新的安全性信号。
核心结论
- 本研究确定了阿法替尼联合放疗、联合或不联合替莫唑胺治疗胶质母细胞瘤的最大耐受剂量。
- 作者认为需要进一步开展阿法替尼治疗胶质母细胞瘤的研究,并应基于适当的生物标志物进行预筛选。
研究设计与样本
- I期、开放标签、3+3剂量递增试验。
- 纳入新诊断、组织学证实的4级恶性胶质瘤且O6-甲基鸟嘌呤-DNA甲基转移酶基因启动子甲基化状态明确的患者。
- 主要终点为连续每日阿法替尼联合放疗(联合或不联合同期替莫唑胺)的最大耐受剂量。
- 55例患者入组,36例接受至少1剂试验药物(方案M 20例,方案U 16例)。
主要发现
- 所有患者在研究期间均停用阿法替尼。
- 停用阿法替尼的原因(方案M/方案U)包括疾病进展(45%/50%)、剂量限制性毒性(10%/0%)和其他不良事件(35%/38%)。
- 两种方案中最常报告的不良事件为腹泻和皮疹,未发现新的安全性信号。
- 联合每日替莫唑胺和放疗时阿法替尼最大耐受剂量为30 mg,仅联合放疗时为40 mg。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Amplification or overexpression of the epidermal growth factor receptor gene, part of the ErbB family, occur in approximately 40% and 60% of patients with GBM, respectively. We present data from a dose-finding study of the ErbB inhibitor afatinib in combination with radiotherapy (RT), with or without temozolomide (TMZ), in patients with GBM. METHODS: This was a phase I, open-label, 3 + 3 dose-escalation trial in patients with newly-diagnosed, histologically-confirmed grade 4 malignant glioma and proven O6-methylguanine-DNA methyltransferase gene promoter methylation status. The primary endpoint was the maximum tolerated dose (MTD) of continuous daily afatinib when given in combination with RT, with (regimen M) or without (regimen U) concomitant TMZ treatment. RESULTS: Fifty-five patients were enrolled; 36 received ≥ 1 dose of trial medication (regimen M, n = 20, regimen U, n = 16). Afatinib was discontinued by all patients during the study. Reasons for afatinib discontinuation (regimen M/U) included disease progression (45%/50%), dose-limiting toxicity (10%/0%), and other adverse events (AEs; 35%/38%). The most frequently reported AEs with either regimen were diarrhea and rash, with no new safety signals identified. The MTD was determined as afatinib 30 mg in combination with daily TMZ and RT, and afatinib 40 mg in combination with RT alone. CONCLUSIONS: This study identified the MTD for afatinib in combination with RT, with and without TMZ, in patients with GBM. Further studies of afatinib in patients with GBM are warranted and should be based on appropriate biomarker-based preselection. TRIAL REGISTRATION: NCT00977431 (first posted September 15, 2009).
引用
- Saran F, Welsh L, James A, et al. Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. J Neurooncol. 2021. PMID: 34787778. doi:10.1007/s11060-021-03877-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。